

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

LUPIN LTD. AND LUPIN PHARMACEUTICALS INC.,

Petitioner

v.

HORIZON THERAPEUTICS, LLC,

Patent Owner

---

Case IPR2017-01159  
Patent 9,254,278

---

**JOINT MOTION TO TERMINATE *INTER PARTES* REVIEW**

**TABLE OF CONTENTS**

I. STATEMENT OF RELIEF REQUESTED .....1

II. STATEMENT OF FACTS .....1

III. RELATED LITIGATION AND INTER PARTES REVIEWS.....3

IV. ARGUMENT .....5

    A. The Board Should Terminate this IPR in its Entirety .....6

    B. Written Settlement Agreement.....7

V. CONCLUSION.....8

**TABLE OF AUTHORITIES**

**Cases**

*Apex Med. Corp. v. Resmed Ltd.*,  
IPR2013-00512, Paper 39 (P.T.A.B. Sept. 12, 2014) .....7

*Plaid Techs., Inc. v. Yodlee, Inc.*,  
IPR2016-00273, Paper 29 (P.T.A.B. Feb. 8, 2017) .....7

*Toyota Motor Corp. v. Blitzsafe Tex. LLC*,  
IPR2016-00421, Paper 28 (P.T.A.B. Feb. 21, 2017) .....6

*Revolution, Inc. v. Versata Software, Inc.*,  
CBM2013-00018, Paper 52 (P.T.A.B. June 17, 2014) .....7

**Statutes**

35 U.S.C. § 317 .....6

35 U.S.C. § 317(a) .....1, 5

35 U.S.C. § 317(b) .....8

**Other Authorities**

Office Patent Trial Practice Guide,  
77 Fed. Reg. 48,756, 48,768 (Aug. 14, 2012) .....6

**Regulations**

37 C.F.R. § 42.107 .....1

37 C.F.R. § 42.72 .....5, 6

37 C.F.R. § 42.74 .....6

37 C.F.R. § 42.74(c)..... 1, 7, 8

## I. STATEMENT OF RELIEF REQUESTED

Pursuant to 35 U.S.C. § 317(a), Lupin Ltd. and Lupin Pharmaceuticals Inc. (collectively “Lupin” or “Petitioner”) and Horizon Therapeutics, LLC (“Horizon” or “Patent Owner”) jointly move that the Board terminate this *inter partes* review (IPR) proceeding, which is directed at U.S. Patent No. 9,254,278 (“the ’278 patent”), in its entirety as a result of settlement between Petitioner and Patent Owner. *See* Ex. 2054 (Confidential).

The parties are concurrently filing a separate request that the settlement agreement (Ex. 2054) being filed herewith be treated as business confidential information and be kept separate from the files of the involved patent, pursuant to 37 C.F.R. § 42.74(c).

## II. STATEMENT OF FACTS

Petitioner filed this IPR petition on March 27, 2017. On July 24, 2017, Patent Owner filed its Preliminary Response under 37 C.F.R. § 42.107. The Board issued a decision instituting *inter partes* review on September 28, 2017. On February 9, 2018, Patent Owner filed its Patent Owner Response. On June 14, 2018, per the parties’ respective requests, the Board ordered a consolidated Oral Argument with IPR2017-01160, directed at related U.S. Patent 9,326,966 (“the ’966 patent”), for July 9, 2018. *See* Paper No. 33.

On June 27, 2018, Petitioner and Patent Owner entered into a settlement agreement. *See* Ex. 2054 (Confidential). Under the terms of the settlement agreement, the parties agreed to jointly seek termination of IPR2017-01159 as well as related *inter partes* review IPR2017-01160, and the parties agreed to dismiss related district court litigation, *Horizon Therapeutics, Inc. v. Lupin Ltd. and Lupin Pharmaceuticals Inc.*, Civil Action No. 1:15-cv-07624-RBK-JS (D.N.J. filed Oct. 19, 2015), and *Horizon Therapeutics, Inc. v. Lupin Ltd. and Lupin Pharmaceuticals Inc.*, Civil Action No. 1:16-cv-4438-RBK-JS (D.N.J. filed Jul. 21, 2016). Thus, this settlement agreement resolves all currently pending Patent Office and District Court proceedings between the parties involving the '278 patent and related '966 patent.

On July 5, 2018, per the request of the parties, the Board cancelled the oral argument scheduled for July 9, 2018, and authorized the parties to file the instant joint motion to terminate the proceedings by no later than July 13, 2018. *See* Paper No. 35. Accordingly, no oral argument has been held and the Board has yet to issue a final decision in this matter.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.